晚期非小细胞肺癌患者一线化疗前后血浆核小体检测及意义

Predictive value of nucleosomes for patients with advanced non-small cell lung cancer that underwent first-line chemotherapy

目的:探讨核小体(nucleosomes)在晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)化疗前后检测的临床意义及早期预测对化疗药物的敏感性。方法:用ELISA试剂盒对66例晚期NSCLC患者血浆中核小体含量进行测定并与以30名健康对照组进行分析。结果:在进行一线化疗前,NSCLC患者核小体水平为215(32～316)ng/mL,显著高于对照者30(2～112)ng/mL,一线药物化疗后,有效组较化疗前显著下降(P<0.05),且与病情稳定及进展者核小体水平有显著的统计学差异(P<0.05)。结论:血浆核小体可作为监测NSCLC化疗中生物化学反应性的有效指标,可能对早期化疗疗效的评价具有重要的指导意义,为个人体化治疗提供方案。

Objective： To explore the clinical significance of nucleosomes in advanced non-small cell lung cancer（NSCLC） patients that underwent chemotherapy and its value for sensitivity prediction.Methods： Plasma nucleosomes content in 66 cases with NSCLC by ELISA kit was detected and compared with that of 30 healthy controls.Results： Before the chemotherapy with first-line drugs,nucleosomes level in NSCLC patients was 215（32～316） ng/mL,significantly higher than 30（2～112） ng/mL of the control group.After chemotherapy,nucleosomes level significant decreased for those showed curative effects which also showed significant difference from patients under stable status or on progress of cancer（P〈0.05）.Conclusions： Plasma nucleosomes can be used for indicators monitoring biochemical reaction during chemotherapy for NSCLC patients,it′s also useful for curative effects evaluation in early stage of chemotherapy.